Skip to main content
Research Areas

Antimicrobial Resistance in India: What the Data Actually Shows

By November 4, 2026No Comments

Most conversations about antibiotic resistance in India happen at a comfortable distance. They are about hospitals, about intensive care units, about superbugs in places most people will never visit. That framing is wrong, and the data on urinary tract infections shows why.

A urinary tract infection is the most ordinary bacterial infection there is. It is treated in a ten-minute consultation at a neighbourhood clinic, usually without a laboratory test, usually with a drug chosen by habit. It is exactly the kind of infection that should be easy. In India, it increasingly is not.

The headline number

In community-acquired urinary tract infections across India — infections picked up in ordinary life, not in hospital — organisms producing extended-spectrum beta-lactamases account for around 44.8% of isolates.

That one statistic deserves unpacking, because it is the centre of the problem.

Extended-spectrum beta-lactamases, usually shortened to ESBLs, are enzymes that bacteria produce to destroy a whole family of antibiotics: the penicillins and the first, second and third generation cephalosporins. These are the drugs that have been the reliable backbone of outpatient infection treatment for decades. Amoxicillin. Cefixime. Ceftriaxone. When a bacterium makes an ESBL, those drugs stop working against it.

So when nearly half of community-acquired urinary pathogens in India are ESBL producers, what that means in practice is that a doctor writing an empirical prescription — a prescription made on clinical judgement, before any culture result — has close to a coin-flip chance of choosing a drug the organism can defeat.

It is not only the cephalosporins

If the problem were confined to one drug class, it would be manageable. It is not.

Surveillance across Indian community settings shows resistance spread across almost every oral option:

  • Ciprofloxacin, long the workhorse of UTI treatment, shows resistance above 45% in E. coli, with regional variation running from roughly 35% to 60%
  • Ampicillin sits above 50%
  • Trimethoprim-sulfamethoxazole, the drug most international guidelines still list first, is above 37%
  • Third-generation cephalosporins range from roughly 32% to 72% depending on the setting

A handful of options remain largely intact. Nitrofurantoin holds up well, with resistance in the range of 6–13%. Amikacin and gentamicin remain broadly effective. Carbapenems — imipenem, meropenem — show resistance in low single digits.

But look at that surviving list carefully. Nitrofurantoin works only for lower urinary tract infection and cannot be used if the kidney is involved. Amikacin and gentamicin are injections. Carbapenems are injections, are expensive, and are generally available only in hospital. The drugs that still work are, with one exception, not drugs you can hand someone at a clinic counter.

Why this happened

Resistance is often discussed as though it were a mysterious biological event. It is not mysterious. It is the predictable result of a set of specific, identifiable practices, and in India four of them dominate.

Treatment without testing. The correct way to treat a urinary infection in a high-resistance environment is to culture the urine, identify the organism, test its susceptibility, and then prescribe. In most Indian primary care that sequence is impossible. Culture and sensitivity testing is concentrated in tertiary hospitals and private laboratories, costs ₹300–1,000, and takes 48–72 hours. The patient in front of the doctor is symptomatic now. So the prescription is empirical, which in a 44.8% ESBL environment means it is frequently wrong, and every wrong prescription is a selection event.

Antibiotics without prescription. Despite being prescription-only in law, antibiotics are widely obtainable over the counter. Self-diagnosis and self-medication are common, and the drug chosen is often inappropriate, the dose often wrong, the course often short.

Courses not finished. Symptoms resolve before the infection is cleared. The patient stops. The surviving organisms are disproportionately the less susceptible ones, and they are the ones that repopulate.

Agriculture. Antibiotic use in Indian livestock and aquaculture is extensive and lightly regulated. This contributes to environmental antibiotic load and to the selection of resistant organisms that reach humans through food and water.

The part that makes it a cycle rather than a trend

The feature of this problem that gets least attention is that treatment failure is not a neutral outcome. It actively worsens the thing that caused it.

When an empirical antibiotic fails against a resistant organism, three things happen at once. The infection persists, so the patient returns and receives a second, usually broader, antibiotic. The failed course has already applied selection pressure, enriching the resistant population. And the antibiotic has disrupted the patient’s own protective bacterial communities — in the gut, and in women, in the vaginal tract — which are a substantial part of what normally prevents the next infection.

That third effect is the one most often missed. A healthy vaginal microbiota dominated by Lactobacillus species is not decorative. It produces lactic acid at concentrations sufficient to inactivate a wide range of competing organisms, and its loss is associated with increased susceptibility to urinary infection. Broad-spectrum antibiotics deplete it. So a failed antibiotic course leaves the patient more susceptible to the next infection than she was before it, while simultaneously making the organism harder to treat.

Infection, antibiotic, failure, more antibiotic, more resistance, more infection. The loop closes.

Where this is heading

Carbapenems are the current backstop for ESBL-producing urinary pathogens in the community, and resistance to them in community isolates remains low. That is genuinely good news, and it is also precarious.

In Indian tertiary hospitals, carbapenem resistance in some Gram-negative organisms has already reached levels that would be alarming if they appeared in the community. The mechanisms that produce it are mobile — they move between bacteria on plasmids, and they move between settings on people. The gap between hospital resistance rates and community resistance rates is a lag, not a wall.

If community carbapenem resistance in urinary pathogens climbs toward the 10–15% range, the practical consequence is untreatable community-acquired urinary tract infection: an ordinary infection, acquired in ordinary life, with no reliable oral treatment and no reliable injectable one either.

That is not a distant hypothetical. It is the straightforward extension of the current trajectory.

What would actually change the trajectory

Three things, in roughly this order of impact.

Diagnostic capacity in primary care. The single highest-leverage intervention is making culture and sensitivity testing available, affordable and fast where infections actually present. Rapid susceptibility testing that returns a result within one consultation would transform prescribing accuracy. Every empirical prescription avoided is a selection event avoided.

Enforcement of prescription-only status. Over-the-counter availability is a policy problem with a policy solution. It is not technically difficult. It is politically and commercially difficult, which is a different thing.

Prevention that does not use antibiotics. If a substantial fraction of recurrent urinary infections are driven by disrupted protective microbiota, then approaches that support those communities rather than destroying them would reduce the number of infections requiring treatment at all. This is an active research area and the evidence is genuinely mixed — several well-conducted trials of probiotic prevention have returned null results, and that should be stated plainly rather than glossed. But the mechanistic rationale is sound and the research is worth doing, because every prevented infection is an antibiotic course not prescribed.

The thing worth remembering

Alexander Fleming, accepting the Nobel Prize in 1945, warned that the easy availability of penicillin would lead to underdosing, that underdosing would educate bacteria to resist it, and that the person who used it carelessly would be morally responsible for the deaths that followed.

He said this in the first year of the antibiotic era, before resistance had become a clinical problem anywhere. He was describing, with considerable precision, the mechanism that has produced a 44.8% ESBL rate in Indian community urinary infections eighty years later.

The information was never the missing piece.


Neuriva Life Sciences is a DPIIT-recognised start-up working on microbiome-based approaches to urogenital health. This article is general information and is not medical advice. If you have symptoms of a urinary tract infection, see a doctor.

Sources

  • Behera B, et al. J Pure Appl Microbiol. 2022;16(3):1847-1856
  • Prabhu MCS, et al. Infect Dis Res Treat. 2022;15:11769344221129844
  • Goel V, et al. JAC-AMR. 2021;3(4):dlab164. doi:10.1093/jacamr/dlab164
  • O’Hanlon DE, Moench TR, Cone RA. BMC Infect Dis. 2011;11:200. doi:10.1186/1471-2334-11-200
  • Ravel J, et al. Proc Natl Acad Sci USA. 2011;108(Suppl 1):4680-4687